Fig. 6

Effect of CER-001 on organ systems and survival. A Evolution of AKI among patients randomized to CER-001, according to KDIGO criteria from baseline (day 1 pre-dose) to day 6. B AKI stages among patients randomized to the Standard of Care group, according to KDIGO criteria from baseline (day 1 pre-dose) to day 6. C–F Serum levels of AST, ALT and albumin measured by the local hospital lab. Data are represented as changes from baseline (day 1 pre-dose) values. Treatment differences were assessed by using a mixed model ANOVA for values on days 3, 6, and 9 with a significance level of α = 0.05; significant pairwise comparisons are shown. No adjustments were made for multiple comparisons. G, H 30-day survival curves for all patients and for ICU patients. Treatment differences were assessed using the log-rank test with a significance level of α = 0.05. Abbreviations: AKI acute kidney injury; ALT Alanine aminotransferase; AST Aspartate aminotransferase